Invivyd Says Study of Potential COVID-19 Treatment Shows 'High End' Efficacy; Measles Candidate Introduced
MT Newswires Live
Apr 09
Invivyd (IVVD) said Thursday that a study of its investigational COVID-19 treatment VYD2311 shows "sufficient statistical power" to achieve the "high end" of anticipated efficacy in an ongoing phase 3 study.
The company said there will be an additional 500 or so participants to the 1,818-patient study, shifting the final results from the original mid-2026 to Q3 2026.
The company also said it has discovered and advanced a novel monoclonal antibody candidate called VMS063 for the treatment and prevention of measles.
The company said it has begun the process of initiating a US Food and Drug Administration investigational new drug application and other regulatory outreach with a target of submitting papers in late 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.